Enhancement of cytotoxic T lymphocyte growth from spleens of P815-tumor-bearing host mice with mafosfamide (Q44904654)

7 December 2017

title

Enhancement of cytotoxic T lymphocyte growth from spleens of P815-tumor-bearing host mice with mafosfamide (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1534514

6 October 2022

0 references

T. H. Inge

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1534514

6 October 2022

S. K. Hoover

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1534514

6 October 2022

J. L. Frank

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1534514

6 October 2022

T. T. Kawabata

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1534514

6 October 2022

K. P. Bethke

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1534514

6 October 2022

H. D. Bear

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1534514

6 October 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1534514

6 October 2022

publication date

1 January 1992

1 reference

Cancer Immunology, Immunotherapy

7 December 2017

published in

1 reference

7 December 2017

volume

35

1 reference

7 December 2017

issue

2

1 reference

7 December 2017

page(s)

119-126

1 reference

Tumor-infiltrating lymphocytes cultured in recombinant interleukin-2: enhancement of growth, cytotoxicity, and phenotypic expression of cytotoxic T-cell antigens by cyclophosphamide given intravenously prior to tumor harvest

7 December 2017

cites work

1 reference

12 December 2020

Aspects of the experimental immunopharmacology of oxazaphosphorines.

1 reference

12 December 2020

Augmentation of delayed-type hypersensitivity by doses of cyclophosphamide which do not affect antibody responses

1 reference

12 December 2020

Cyclophosphamide (Cy)-facilitated adoptive immunotherapy of a Cy-resistant tumour. Evidence that Cy permits the expression of adoptive T-cell mediated immunity by removing suppressor T cells rather than by reducing tumour burden.

1 reference

12 December 2020

Relative susceptibilities of T cell subsets involved in delayed-type hypersensitivity to sheep red blood cells to the in vitro action of 4-hydroperoxycyclophosphamide

1 reference

12 December 2020

Characterization of cells from invaded lymph nodes in patients with solid tumors. Lymphokine requirement for tumor-specific lymphoproliferative response

1 reference

12 December 2020

Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells

1 reference

12 December 2020

In vitro effects of 4-hydroperoxycyclophosphamide on concanavalin A-induced human suppressor T cells

1 reference

12 December 2020

Ly 1+2- suppressor T cells down-regulate the generation of Ly 1-2+ effector T cells during progressive growth of the P815 mastocytoma

1 reference

12 December 2020

Production of tumor-specific suppressor T cell hybridomas

1 reference

12 December 2020

Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+,2- T cells. Tumor eradication does not require participation of cytotoxic T cells

1 reference

12 December 2020

Enhancement of in vivo and in vitro murine immune responses by the cyclophosphamide metabolite acrolein

1 reference

12 December 2020

Oxazaphosphorines as biological response modifiers--experimental and clinical perspectives

1 reference

12 December 2020

In vitro expression of secondary antitumor immunity by in vitro tumor-sensitized T cells: inhibition by tumor-induced suppressor T cells.

1 reference

12 December 2020

Activation mechanisms of mafosfamide and the role of thiols in cyclophosphamide metabolism

1 reference

12 December 2020

Possible role of acrolein in oxazaphosphorine-induced enhancement of immunological reactivity

1 reference

12 December 2020

In vitro effects of 4-hydroxyperoxycyclophosphamide on human immunoregulatory T subset function.

1 reference

12 December 2020

Oxazaphosphorine effects in L 5222 rat leukemia

1 reference

12 December 2020

Preclinical and early clinical trial with mafosfamide as immune modulator.

1 reference

12 December 2020

Cyclophosphamide and abrogation of tumor-induced suppressor T cell activity

1 reference

12 December 2020

In vitro effects of 4-hydroperoxycyclophosphamide on human immunoregulatory T subset function. I. Selective effects on lymphocyte function in T-B cell collaboration

1 reference

12 December 2020

Oxazaphosphorine cytostatics: past-present-future. Seventh Cain Memorial Award lecture

1 reference

12 December 2020

Augmentation of host antitumor immunity by low doses of cyclophosphamide and mafosfamide in two animal tumor models

1 reference

12 December 2020

Some advantages of curing mice bearing a large subcutaneous MOPC-315 tumor with a low dose rather than a high dose of cyclophosphamide

1 reference

12 December 2020

Direct in vitro evidence for different susceptibilities to 4-hydroperoxycyclophosphamide of antigen-primed T cells regulating humoral and cell-mediated immune responses to sheep erythrocytes: a possible explanation for the inverse action of cyclopho

1 reference

12 December 2020

Cyclophosphamide-sensitive T lymphocytes suppress the in vivo generation of antigen-specific cytotoxic T lymphocytes

1 reference

12 December 2020

Cyclophosphamide-induced immunologically mediated regression of a cyclophosphamide-resistant murine tumor: a consequence of eliminating precursor L3T4+ suppressor T-cells.

1 reference

12 December 2020

Tumor-specific suppressor T-cells which inhibit the in vitro generation of cytolytic T-cells from immune and early tumor-bearing host spleens.

1 reference

12 December 2020

Activation and expansion of cytotoxic T lymphocytes from tumor-draining lymph nodes

1 reference

12 December 2020

Role of antitumor immunity in cyclophosphamide-induced rejection of subcutaneous nonpalpable MOPC-315 tumors.

1 reference

12 December 2020

Differential cyclophosphamide sensitivity of suppressor and cytotoxic cell precursors

1 reference

12 December 2020

The Effect of Cyclophospkamide on the Immune Response

1 reference

12 December 2020

Phenotype of syngeneic tumor-specific cytotoxic T-lymphocytes and requirements for their in vitro generation from tumor-bearing host and immune spleens

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF01741859

1 reference

7 December 2017

1 reference